论文部分内容阅读
目的采用自体造血干细胞移植后完全缓解的血液肿瘤患者的外周血单个核细胞,经体外培养扩增出树突状细胞(dendritic cell DC)/细胞因子诱导的杀伤细胞(cytokine induced killer cell CIK),应用DC/CIK细胞免疫治疗自体造血干细胞移植后完全缓解血液肿瘤患者,观察其不良反应。方法采集10例血液肿瘤自体造血干细胞移植后完全缓解患者的外周血单个核细胞,在体外经GM-CSF、IL-4、TNF-α等诱导产生DC,经IFN-γ、抗CD3单抗、IL-2等诱导产生CIK,观察其细胞形态及临床应用的不良反应并分析其细胞免疫表型。结果培养产生形态学典型的DC/CIK。诱导成熟的DC经流式细胞仪分析显示CD80、CD83、CD86、CD1a等阳性细胞比率大幅上升。CIK随着培养时间的延长,CD3+CD56+、CD3+CD8+双阳性细胞的比率亦大幅度上升。在DC/CIK细胞免疫治疗过程中,3例患者DC注射部位出现轻微疼痛,可自行缓解。2例患者输注CIK后出现低热,持续时间2～6h,可自行消退。4例患者输注完CIK后出现乏力,约2h可自行缓解。结论自体造血干细胞移植后完全缓解患者的外周血单个核细胞对DC/CIK的培养不受影响。DC/CIK细胞免疫治疗自体造血干细胞移植后完全缓解的血液肿瘤患者,安全性好,不良反应少。
Objective To investigate the effect of dendritic cell DC / cytokine induced killer cell (CIK) on peripheral blood mononuclear cells (PBMCs) in peripheral blood of patients with complete remission after hematopoietic stem cell transplantation. Application of DC / CIK cellular immunotherapy in patients with hematopoietic tumors after complete autologous hematopoietic stem cell transplantation to observe the adverse reactions. Methods Peripheral blood mononuclear cells (PBMCs) of 10 patients with complete remission after hematopoietic stem cell transplantation were collected and induced by GM-CSF, IL-4 and TNF-α in vitro. DCs were induced by IFN-γ, IL-2 and other induced CIK to observe the cell morphology and clinical adverse reactions and analysis of their cellular phenotype. Results Culture produced DC / CIK typical of morphology. The induction of mature DC by flow cytometry analysis showed that CD80, CD83, CD86, CD1a and other positive cells increased dramatically. CIK With the extension of culture time, the ratio of CD3 + CD56 +, CD3 + CD8 + double positive cells also increased significantly. During DC / CIK cellular immunotherapy, mild pain was found in the DC injection site in 3 patients and relieved spontaneously. Two patients showed hypothermia after infusion of CIK, the duration of 2 ~ 6h, spontaneous regression. 4 patients after infusion of CIK appeared fatigue, about 2h relieve itself. Conclusion Peripheral blood mononuclear cells from patients with complete remission after autologous hematopoietic stem cell transplantation have no effect on the culture of DC / CIK. DC / CIK Cellular Immunotherapy Patients with complete remission of hematologic malignancies after autologous hematopoietic stem cell transplantation have good safety and few adverse reactions.